Robbins Farley
BMY icon

Robbins Farley’s Bristol-Myers Squibb BMY Stock Holding History

Robbins Farley’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$44.8K Sell
718
-3
-0.4% -$190 0.02% 91
2026
Q2 		$41.5K Sell
721
-182
-20% -$10.5K 0.02% 91
2026
Q1 		$54.8K Hold
903
– – 0.02% 80
2025
Q4 		$48.7K Buy
903
+276
+44% +$13.3K 0.02% 81
2025
Q3 		$28.3K Buy
627
+167
+36% +$7.8K 0.01% 98
2025
Q2 		$21.3K Hold
460
– – 0.01% 102
2025
Q1 		$28.1K Sell
460
-100
-18% -$5.83K 0.01% 88
2024
Q4 		$31.7K Hold
560
– – 0.02% 90
2024
Q3 		$29K Sell
560
-330
-37% -$15.5K 0.01% 89
2024
Q2 		$37K Sell
890
-142
-14% -$6.35K 0.02% 82
2024
Q1 		$56K Buy
1,032
+191
+23% +$9.7K 0.03% 76
2023
Q4 		$43.2K Sell
841
-19
-2% -$997 0.03% 79
2023
Q3 		$49.9K Sell
860
-31,721
-97% -$1.94M 0.03% 78
2023
Q2 		$2.08M Sell
32,581
-1,102
-3% -$73.9K 1.44% 32
2023
Q1 		$2.33M Buy
33,683
+1,449
+4% +$102K 1.56% 30
2022
Q4 		$2.32M Sell
32,234
-11,208
-26% -$845K 1.79% 27
2022
Q3 		$3.09M Sell
43,442
-1,094
-2% -$79.4K 2.54% 11
2022
Q2 		$3.43M Sell
44,536
-6,348
-12% -$483K 3.57% 7
2022
Q1 		$3.72M Sell
50,884
-3,705
-7% -$249K 2.8% 11
2021
Q4 		$3.4M Buy
54,589
+5,083
+10% +$298K 2.52% 16
2021
Q3 		$2.93M Sell
49,506
-5,352
-10% -$352K 2.16% 15
2021
Q2 		$3.67M Buy
54,858
+6,465
+13% +$422K 4.14% 8
2021
Q1 		$3.13M Buy
48,393
+1,682
+4% +$105K 2.76% 10
2020
Q4 		$2.9M Buy
+46,711
New +$2.87M 2.85% 10

Other funds holding BMY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Robbins Farley's BMY Position: Q3 2026 in Review

Robbins Farley reduced its Bristol-Myers Squibb (BMY) stake by 0.42% in Q3 2026, selling an estimated $190 and leaving 718 shares worth $44.8K. The position accounts for 0.02% of the portfolio, ranked #91.

Robbins Farley first reported a position in BMY in Q4 2020 and has held it in 24 quarters since. The position peaked at $3.72M in Q1 2022. 598 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Robbins Farley held 718 shares of Bristol-Myers Squibb worth $44.8K as of Q3 2026.
  • Robbins Farley sold 3 Bristol-Myers Squibb shares in Q3 2026, an estimated $190.
  • Bristol-Myers Squibb made up 0.02% of Robbins Farley's portfolio in Q3 2026, its #91 holding.
  • Robbins Farley first reported a position in Bristol-Myers Squibb in Q4 2020 and has held it in 24 quarters since.
  • Robbins Farley's Bristol-Myers Squibb position peaked at $3.72M in Q1 2022.
  • 598 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Robbins Farley's 13F filing for Q3 2026, filed 21 Oct 2026.